 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 851552
Online Users : 888
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/12701
|
| Title: | A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
| Authors: | Wang-Gillam, A;Hubner, R;Mirakhur, B;de Jong, F;Belanger, B;Chen, LT |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Background: NAPOLI-1 (NCT01494506) was a global phase 3 study in pts with mPDAC previously treated with gemcitabine-based therapy that showed a significant improvement in overall survival (OS) in pts treated with nal-IRI+5-FU/LV vs 5-FU/LV alone. A nomogram assists in predicting individualized risk for prespecified events, such as OS, death, or adverse events. A post hoc analysis of NAPOLI-1 was conducted to develop a nomogram to predict OS for nal-IRI+5-FU/LV in the post-gemcitabine setting. Methods: In NAPOLI-1, pts received nal-IRI+5-FU/LV, nal-IRI, or 5-FU/LV. Univariate and multivariate analyses identified baseline factors that were significantly predictive of OS. A multivariable Cox regression model was created to develop a nomogram that assigned points equal to the weighted sum of relative significance of each variable. The predictive accuracy of the nomogram, as measured by the concordance index (c-index), was evaluated by internal bootstrap validation. Results: Data from pts in the univariate analysis (n = 417) and multivariate analysis (n = 399; n = 18 pts excluded for missing data) were used. Eight of 21 variables were retained in the multivariate analysis and re-tested through stratification (all factors significant at the P < 0.01 level, except BMI [P= 0.08]). Conclusions: Key predictors of OS in NAPOLI-1 were nal-IRI+5-FU/LV treatment, KPS, NLR, albumin level, baseline CA19-9, stage 4 at diagnosis, BMI, and presence of liver metastasis. |
| Date: | 2018-05 |
| Relation: | Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Meeting Abstract e16204. |
| Link to: | http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e16204 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000442916005318 |
| Appears in Collections: | [陳立宗] 會議論文/會議摘要
|
Files in This Item:
There are no files associated with this item.
|
All items in NHRI are protected by copyright, with all rights reserved.
|
